drugset / Trial / NCT05353673
The Combination of Sitagliptin and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
RandomizedParallel-groupOpen-labelTreatment
Summary
Randomized, open-label, multicenter study to compare the efficacy and safety of combination of Sitagliptin and danazol versus danazol for the treatment of adults with steroid-resistant/relapse immune thrombocytopenia (ITP).
Timeline
- Start
- 2021-06-01
- Primary completion
- 2022-12-01
- Completion
- 2023-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Danazol | Other / unclassified | 200 mg | Oral |
| Subject | Sitagliptin | Small molecule | 100 mg/m2 | Oral |